Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is making significant strides in precision oncology as it advances its lead candidate, ONC010, toward first-in-human studies. The company has initiated crucial manufacturing and analytical characterization activities with Nanosoft Polymers, alongside metabolism studies with Nucro-Technics, as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010's metabolic profile, and generate essential data for future pharmacokinetic, toxicology, and regulatory activities.
ONC010 is a nanoparticle-encapsulated inhibitor of polynucleotide kinase/phosphatase (PNKP), an enzyme involved in DNA repair. By targeting PNKP, ONC010 aims to exploit vulnerabilities in cancer cells with defective DNA damage response mechanisms. The nanoparticle delivery system is intended to enhance the drug's bioavailability and tumor targeting while reducing systemic toxicity. This approach is particularly relevant as precision medicine continues to expand, with treatments increasingly tailored to specific genetic biomarkers.
The collaboration with Nanosoft Polymers focuses on polymer process development and analytical characterization, which are critical for ensuring the consistency and quality of the nanoparticle formulation. Meanwhile, the metabolism studies with Nucro-Technics will provide insights into how ONC010 is processed in the body, a key component of the IND application. These initiatives lay the groundwork for scalable manufacturing, a necessary step for eventual clinical trials and commercialization.
Onco-Innovations' strategy is underpinned by its AI-driven discovery capabilities, which help identify patient populations most likely to benefit from PNKP inhibition. By combining targeted therapy with advanced drug delivery and artificial intelligence, the company is positioning its platform to pursue cancers that may be particularly susceptible to DNA damage response approaches. This integrated approach could potentially lead to more effective and less toxic cancer treatments.
The company has secured an exclusive worldwide license to patented technology targeting solid tumors, and its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. As Onco-Innovations progresses ONC010 through the preclinical pipeline, the data generated from these manufacturing and metabolism studies will be pivotal in advancing toward clinical trials. For more information about Onco-Innovations and its pipeline, visit the company's website at https://oncoinnovations.com/.
